Biomimetic Therapeutics

biomimetic therapeutics (nasdaq: bmti) is a biotechnology company specializing in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications. all augment branded products are based upon recombinant human platelet-derived growth factor (rhpdgf-bb), which is an engineered form of pdgf, one of the body's principal agents to stimulate and direct healing and regeneration. through the commercialization of this patented technology, biomimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments. biomimetic received regulatory approval in 2009 and 2011 to market augment in canada, and in australia for hindfoot and ankle fusion indications. augment is pending regulatory decisions in the u.s. and european union for similar indications.